Technology is at the heart of our team's passion.

Our first two FDA-cleared products, the T2Candida Panel and T2Dx Instrument, use T2MR technology to accurately detect Candida – a sepsis-causing bloodstream infection – in an average of 4.3 hours with no blood culture. This rapid detection can help physicians to lower Candida’s 40% mortality rate to 11%.1,2 And this is only the beginning. We are developing products for rapid bacteria detection and hemostasis measurements, which could impact over 11 million patients. We’ve also entered into a partnership with Canon U.S. Life Sciences to improve the detecton of Lyme disease-causing pathogens – a debilitating disease where 3.4 million tests are performed on patients annually.  

Learn more about our culture of innovation and collaboration.



1. Morrell, M., Fraser, V. J., and Kollef, M. H. (2005). Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityAntimicrobial agents and chemotherapy, 49(9), 3640-3645. 
2. Garey, K. W., Rege, M., Pai, M. P., et. al. (2006). Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional studyClinical infectious diseases, 43(1), 25-31.